MedPath

To study the effect of drugs given directly into the arteries feeding the liver cancer along with heat induced changes on liver cancer outcome as assessed by Computed tomography.

Phase 4
Conditions
Health Condition 1: K768- Other specified diseases of liver
Registration Number
CTRI/2022/10/046766
Lead Sponsor
Indian Council Of Medical Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. BCLC stage B with Child Pugh A or B

2. Main portal vein patent

3. No extrahepatic spread

4. No previous treatment for Hepatocellular Carcinoma

5. Coagulation parameters suitable for TACE.

Exclusion Criteria

1. Uncorrectable Coagulopathy

2. Refractory Ascites

3. Hepatic Encephalopathy

4. Esophageal/ Variceal bleeding

5. Allergic to contrast

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1] modified Response Evaluation Criteria in Solid Tumors (mRECIST) used for response evalution <br/ ><br>2]at 1,3,6,12 months after intervention by Triple phase CT /MRI scan.Timepoint: 12 months.
Secondary Outcome Measures
NameTimeMethod
liver function tests <br/ ><br> <br/ ><br>Timepoint: 1,3,6,12 months after intervention
© Copyright 2025. All Rights Reserved by MedPath